Early mortality of stage IV non-small cell lung cancer in the United States

References

• Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004;59:602–607.
   PubMed Web of Science ®Google Scholar
• Jorgensen TL, Hallas J, Friis S, et al. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106:1353–1360.
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, et al. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015;26:902–907.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Lung Guidelines [Internet]. [cited 2018 Dec 19]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#nscl
   Google Scholar
• Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25:1475–1484.
   PubMed Web of Science ®Google Scholar
• Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res. 2004;10:4258s–4262s.
   PubMed Web of Science ®Google Scholar
• Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005;23:3235–3242.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy (LCT) improves overall survival (OS) compared to maintenance therapy/observation in oligometastatic non-small cell lung cancer (NSCLC): final results of a multicenter, randomized, controlled phase 2 trial. Int J Radiat Oncol Biol Phys. 2018;102:1604.
   Web of Science ®Google Scholar
• Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson RA, Harrow S, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic ss (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys. 2018;102:S3–S4.
   Web of Science ®Google Scholar
• Bilimoria KY, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–690.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–125.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–1682.
   PubMed Web of Science ®Google Scholar
• Mendez JA, Benjamín D, Lorente D, et al. Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy. JCO. 2018;36:e21089.
   Web of Science ®Google Scholar
• Li S, Zhu R, Li D, et al. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2018;10:3701–3713.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines. Older adult oncology. Version 2 [Internet]. [cited 2018 Dec 26]. Available from: https://www.nccn.org/
   Google Scholar
• Hamaker ME, Jonker JM, de Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13:e437–e444.
   PubMed Web of Science ®Google Scholar
• Verma V. Economic sustainability of immune-checkpoint inhibitors: the looming threat. Nat Rev Clin Oncol. 2018;15:721–722.
   PubMed Web of Science ®Google Scholar
• Verma V, Shah C, Rwigema JC, et al. Cost-comparativeness of proton versus photon therapy. Chin Clin Oncol. 2016;5:56.
   PubMed Web of Science ®Google Scholar
• Ma M, Shen J, Jiang L, et al. Prognostic factors in patients with stage IV non-small cell lung cancer. Chinese German J Clin Oncol. 2006;5:319–323.
   Google Scholar
• Skaug K, Eide GE, Gulsvik A. Predictors of long-term survival of lung cancer patients in a Norwegian community. Clin Respir J. 2011;5:50–58.
   PubMed Web of Science ®Google Scholar
• Unger JM, Cook E, Tai E, et al. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–198.
   PubMedGoogle Scholar
• Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol. 2016;7:325–333.
   PubMed Web of Science ®Google Scholar